Prevention Of Respiratory Distress Syndrome; | Stock Market News & Stocks to Watch from StraightStocks

PWRM, ATU, AQNM, DSCO, TSTR, CHIP, DrStockPick.com Stock Report!

Dr. Stock Pick (September 30th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

PWRM, ATU, AQNM, DSCO, TSTR, CHIP

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to

...

Tags for this Post:
Actuant Corporation, Actuation Systems, advertisement services, ALS, Aquentium Inc.;, AT&T Inc., ATU, Beijing, Biotechnology, Breast Cancer, broker, Canada, cancer, Chair and Keynote Speaker, Chemicals, chief scientific officer, China, Congress, Crown Equity Holdings Inc.;, diagnostic tests, Discovery Laboratories Inc;, Discovery Labs, Dr Stock Pick, Dsco, e-coli, equity trader, Fda, Food Processors, green technologies;, Houston, improved food safety standards, industrial products, integrated satellite, integrated satellite wireless communications, International Congress, Internet Protocol, Investing Lessons, Ira Goldknopf, KL4 Surfactant Technology, mobile communication services, neurodegenerative disease;, non-chemical process;, non-chemical processing, non-chemical sanitation equipment, non-chemical technology, North America, Phase Ii, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, president, prevention of respiratory distress syndrome;, professional investment analyst and consultant, public relations services, RECEPTORS LLC;, sanitation equipment, satellite phone, selective binding products, stock featured on our site;, Stock Pick, Stocks to Watch, Surfaxin(R) (lucinactant), Technology, TerreStar Corporation, TerreStar Networks Inc., terrestrial communications network, Texas, Therapies for respiratory diseases, U.S. Food and Drug Administration, United States, United States Food and Drug Administration, VeriChip Corporation, wireless communications, www.aquentium.com, www.crowntradingsystems.com, www.crwenews.com, www.drstockpick.com, www.power3medical.com, www.stock-ir.com

Posted in Investing Lessons, Stocks to Watch | No Comments »

Updated Calendar of 12 Extreme Trades on Pending FDA Decisions

Bullish Bankers (May 22nd, 2009) Writes:

Below are 12 extreme FDA trades for 11 companies with market caps below $200M which have pending new drug product decisions or other meetings/milestones scheduled with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in extreme FDA and Clinical Trial Calendar trades, which are highlighted in periodic articles at BioMedReports.com.

Hemispherx Biopharma [HEB: 1.36, -0.10 (-6.85%)]: Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no

...

Tags for this Post:
Acute Myeloid Leukemia, Anti-Infective Drugs Advisory Committee;, Arthritis, breakthrough cancer pain;, bullish bankers, C12U;, chronic fatigue syndrome;, clinical drug product;, colorectal cancer, Committee for Medicinal Products for Human Use, Depression, drug product;, DSCO Discovery Labs;, european commission, European Medicines Agency, European Union, Fda, Fentanyl;, Financial, Fusilev;, heart failure, HEB;, inflammation, insomnia, Labcorp, Lymphoma, Market Commentary, Meda Ab, medicinal products, Memorial Day, Mike Havrilla, nerve pain, neuralgia, pain, pneumonia, prevention of respiratory distress syndrome;, Qutenza(TM);, Qutenza;, Spectrum Pharmaceuticals Inc, treatment for chronic fatigue syndrome;, treatment of chronic heart failure, treatment of depression, Tse, United States, USD, VNP40101M;

Posted in Financial, Market Commentary | No Comments »

A Dozen Extreme FDA Trades on New Product Decisions

Bullish Bankers (April 13th, 2009) Writes:

Below are 12 companies with market caps below $200M which have pending new drug product decisions at the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced.

BioMedReports.com FDA Calendar

1.) Vion Pharma (VION.OB): Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA (filed with the FDA on 2/17/09) with priority review request as a single agent for remission induction treatment for patients age 60 and older with de novo poor-risk acute myeloid leukemia (AML). 4/17/09 is date for FDA to accept the filing and rule on priority review request - if granted the PDUFA would be 8/17/09 instead of 12/17/09 for standard 10-month review.

2.) Discovery Labs (DSCO): Surfaxin (lucinactant) NDA for prevention of respiratory distress syndrome (RDS) in premature infants. DSCO received its third approvable letter for Surfaxin last

...